Extension of the Cancer Immunotherapy Pilot Program
保存版の掲載情報です。最新の営業状況・料金・利用条件は出典をご確認ください。
保存されている情報
On June 29, 2016, the United States Patent and Trademark Office (USPTO) implemented the Cancer Immunotherapy Pilot Program, which permits patent applications pertaining to cancer immunotherapy to be advanced out of turn for examination and reviewed earlier (accorded special status). To date, over 80 petitions requesting participation in the pilot program have been filed, and 9 patents have been granted under the pilot program. Various stakeholders from around the world have filed petitions to participate in the pilot program--they are independent inventors, universities, research institutions, hospitals, medical centers, government agencies, and large and small companies. The pilot program was originally scheduled to end on June 28, 2017. In view of the continued interest in the pilot program, the USPTO is extending the pilot program until December 31, 2018. All pilot parameters will remain the same as the original pilot.
- Current entry point
- www.federalregister.gov/documents/2017/06/23/2017-13122/extension-of-the-cancer-immunotherapy-pilot-program (permanent link in the Federal Register, verified 2026-09-30)
- Legacy system and where it moved
- No legacy system name mention in title or summary )
- Fee
- No fee mention in title or summary )
- What you need (account or API key)
- No account or key mention in title or summary )
- Published
- 2017-06-23
- Document type
- Notice
原データ更新日：2026-10-06
保存版に記録された日付です。今回の実装・デプロイ日ではありません。